Aprea Therapeutics Inc. announced its financial results for the third quarter ended September 30, 2025, and provided a business update. The company reported continued progress in its WEE1 and ATR inhibitor programs and stated it has a cash runway into the fourth quarter of 2026. In the ongoing Phase 1 ACESOT-1051 dose-escalation trial for APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, according to RECIST v1.1, among heavily pretreated patients with gastrointestinal and gynecologic malignancies. The company has recently advanced to the 150 mg once daily cohort as dose escalation continues. For ATRN-119, an ATR kinase inhibitor, the recommended Phase 2 dose (RP2D) of 1,100 mg once daily was identified in the ABOYA-119 dose-escalation study. Aprea is considering potential combination strategies for ATRN-119, including with radiation or checkpoint inhibitors. Posters with updated data for both APR-1051 and ATRN-119 were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The company anticipates clinical catalysts in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109860), on November 12, 2025, and is solely responsible for the information contained therein.
Comments